Kiniksa Pharmaceuticals
KNSA
103 hedge funds and large institutions have $346M invested in Kiniksa Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 41 increasing their positions, 27 reducing their positions, and 20 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 27
31% more call options, than puts
Call options by funds: $3.67M | Put options by funds: $2.79M
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
2% more funds holding
Funds holding: 101 → 103 (+2)
5% more capital invested
Capital invested by funds: $330M → $346M (+$15.8M)
2.46% less ownership
Funds ownership: 89.31% → 86.85% (-2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.47M |
| 2 |
Renaissance Technologies
New York
|
+$3.73M |
| 3 |
Millennium Management
New York
|
+$3.69M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.99M |
| 2 |
LPC
Lion Point Capital
New York
|
-$5.42M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.5M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
-$3.31M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$2.67M |
KNSA Hedge Fund Activity: Q4 2021 in Review
103 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2021, worth a combined $346M — up 4.8% from $330M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new KNSA positions and 20 closed out — a net gain of 2 holders — while 41 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $4.47M. The largest seller was State Street, cutting an estimated $6.99M.
- 103 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2021, up from 101 in Q3 2021.
- Funds reported $346M of Kiniksa Pharmaceuticals stock for Q4 2021, up 4.8% quarter-over-quarter.
- 22 funds opened new Kiniksa Pharmaceuticals positions in Q4 2021 and 20 closed out, a net change of +2 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $4.47M added.
- The largest Kiniksa Pharmaceuticals seller in Q4 2021 was State Street, an estimated $6.99M sold.
Based on aggregated 13F filings for Q4 2021.